Using transgenic plants and modified plant viruses for the development of treatments for human diseases

Curr Opin Virol. 2017 Oct:26:81-89. doi: 10.1016/j.coviro.2017.07.019. Epub 2017 Aug 8.

Abstract

Production of proteins in plants for human health applications has become an attractive strategy attributed by their potentials for low-cost production, increased safety due to the lack of human or animal pathogens, scalability and ability to produce complex proteins. A major milestone for plant-based protein production for use in human health was achieved when Protalix BioTherapeutics produced taliglucerase alfa (Elelyso®) in suspension cultures of a transgenic carrot cell line for the treatment of patients with Gaucher's disease, was approved by the USA Food and Drug Administration in 2012. In this review, we are highlighting various approaches for plant-based production of proteins and recent progress in the development of plant-made therapeutics and biologics for the prevention and treatment of human diseases.

Publication types

  • Review

MeSH terms

  • Biological Products / metabolism*
  • Biotechnology / methods
  • Genetic Vectors*
  • Humans
  • Plant Viruses / genetics*
  • Plants, Genetically Modified / genetics*
  • Plants, Genetically Modified / virology*
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism*
  • Technology, Pharmaceutical / methods

Substances

  • Biological Products
  • Recombinant Proteins